clinical responses
tumor neoantigens
tumor immunity
relevant T cell responses
anti-cancer immune responses
course of NACR
neoantigen-specific T cell responses
efficient anti-tumor T cell response capable of controlling tumor progression
Tumor neo-antigens
mechanisms of response
effects of immunogenic chemoradiation
patients
question
complete pathological response
immune landscape ofesophageal cancers Esophageal carcinoma
immune checkpoint blockade immunotherapy
fraction of ECs
deadliest cancers
mutated cancer genes
longterm effects of successful treatments
non-responding ones
pre-operative
high-throughput platform
CPR
stimulation
current standard therapy
implementation
long-term survival
proof
design
tumors
activation
concept study
efficacious therapies
Evidence
surgery
Objective